Global Anti-VEGF Ophthalmic Drugs Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Anti-VEGF ophthalmic drugs are medications specifically designed to inhibit vascular endothelial growth factor(VEGF),a protein that plays a critical role in promoting abnormal blood vessel growth in the eye.These drugs are used primarily in the treatment of eye conditions such as wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema,where excessive VEGF activity contributes to vision loss.
The global Anti-VEGF Ophthalmic Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Ophthalmic Drugs Industry Forecast” looks at past sales and reviews total world Anti-VEGF Ophthalmic Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Ophthalmic Drugs sales for 2024 through 2030. With Anti-VEGF Ophthalmic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Ophthalmic Drugs industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Ophthalmic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Ophthalmic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Ophthalmic Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Ophthalmic Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Ophthalmic Drugs.
United States market for Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Anti-VEGF Ophthalmic Drugs players cover Roche, Novartis, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Ophthalmic Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Anti-VEGF Ophthalmic Drugs market?
What factors are driving Anti-VEGF Ophthalmic Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-VEGF Ophthalmic Drugs market opportunities vary by end market size?
How does Anti-VEGF Ophthalmic Drugs break out by Type, by Application?
Anti-VEGF ophthalmic drugs are medications specifically designed to inhibit vascular endothelial growth factor(VEGF),a protein that plays a critical role in promoting abnormal blood vessel growth in the eye.These drugs are used primarily in the treatment of eye conditions such as wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema,where excessive VEGF activity contributes to vision loss.
The global Anti-VEGF Ophthalmic Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Anti-VEGF Ophthalmic Drugs Industry Forecast” looks at past sales and reviews total world Anti-VEGF Ophthalmic Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Ophthalmic Drugs sales for 2024 through 2030. With Anti-VEGF Ophthalmic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Ophthalmic Drugs industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Ophthalmic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Ophthalmic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Ophthalmic Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Ophthalmic Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Ophthalmic Drugs.
United States market for Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Anti-VEGF Ophthalmic Drugs players cover Roche, Novartis, Coherus BioSciences, Regeneron Pharmaceuticals, Samsung Bioepis, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Ophthalmic Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Monoclonal Antibodies
- Fusion Proteins
- Age-related Macular Degeneration
- Diabetic Retinopathy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Novartis
- Coherus BioSciences
- Regeneron Pharmaceuticals
- Samsung Bioepis
- Biocon Biologics
- Chengdu Kanghong Pharmaceutical
What is the 10-year outlook for the global Anti-VEGF Ophthalmic Drugs market?
What factors are driving Anti-VEGF Ophthalmic Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-VEGF Ophthalmic Drugs market opportunities vary by end market size?
How does Anti-VEGF Ophthalmic Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Ophthalmic Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-VEGF Ophthalmic Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-VEGF Ophthalmic Drugs by Country/Region, 2019, 2023 & 2030
2.2 Anti-VEGF Ophthalmic Drugs Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Fusion Proteins
2.3 Anti-VEGF Ophthalmic Drugs Sales by Type
2.3.1 Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-VEGF Ophthalmic Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-VEGF Ophthalmic Drugs Sale Price by Type (2019-2024)
2.4 Anti-VEGF Ophthalmic Drugs Segment by Application
2.4.1 Age-related Macular Degeneration
2.4.2 Diabetic Retinopathy
2.4.3 Other
2.5 Anti-VEGF Ophthalmic Drugs Sales by Application
2.5.1 Global Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-VEGF Ophthalmic Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-VEGF Ophthalmic Drugs Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Anti-VEGF Ophthalmic Drugs Breakdown Data by Company
3.1.1 Global Anti-VEGF Ophthalmic Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Company (2019-2024)
3.2 Global Anti-VEGF Ophthalmic Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-VEGF Ophthalmic Drugs Revenue by Company (2019-2024)
3.2.2 Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Anti-VEGF Ophthalmic Drugs Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Ophthalmic Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Ophthalmic Drugs Product Location Distribution
3.4.2 Players Anti-VEGF Ophthalmic Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF OPHTHALMIC DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Ophthalmic Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-VEGF Ophthalmic Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-VEGF Ophthalmic Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-VEGF Ophthalmic Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-VEGF Ophthalmic Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-VEGF Ophthalmic Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-VEGF Ophthalmic Drugs Sales Growth
4.4 APAC Anti-VEGF Ophthalmic Drugs Sales Growth
4.5 Europe Anti-VEGF Ophthalmic Drugs Sales Growth
4.6 Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Ophthalmic Drugs Sales by Country
5.1.1 Americas Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024)
5.1.2 Americas Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024)
5.2 Americas Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2024)
5.3 Americas Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Ophthalmic Drugs Sales by Region
6.1.1 APAC Anti-VEGF Ophthalmic Drugs Sales by Region (2019-2024)
6.1.2 APAC Anti-VEGF Ophthalmic Drugs Revenue by Region (2019-2024)
6.2 APAC Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2024)
6.3 APAC Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Ophthalmic Drugs by Country
7.1.1 Europe Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024)
7.1.2 Europe Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024)
7.2 Europe Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2024)
7.3 Europe Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Ophthalmic Drugs by Country
8.1.1 Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2024)
8.3 Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Ophthalmic Drugs
10.3 Manufacturing Process Analysis of Anti-VEGF Ophthalmic Drugs
10.4 Industry Chain Structure of Anti-VEGF Ophthalmic Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Ophthalmic Drugs Distributors
11.3 Anti-VEGF Ophthalmic Drugs Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF OPHTHALMIC DRUGS BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Ophthalmic Drugs Market Size Forecast by Region
12.1.1 Global Anti-VEGF Ophthalmic Drugs Forecast by Region (2025-2030)
12.1.2 Global Anti-VEGF Ophthalmic Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Anti-VEGF Ophthalmic Drugs Forecast by Type (2025-2030)
12.7 Global Anti-VEGF Ophthalmic Drugs Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.1.3 Roche Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.2.3 Novartis Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Coherus BioSciences
13.3.1 Coherus BioSciences Company Information
13.3.2 Coherus BioSciences Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.3.3 Coherus BioSciences Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Coherus BioSciences Main Business Overview
13.3.5 Coherus BioSciences Latest Developments
13.4 Regeneron Pharmaceuticals
13.4.1 Regeneron Pharmaceuticals Company Information
13.4.2 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.4.3 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Regeneron Pharmaceuticals Main Business Overview
13.4.5 Regeneron Pharmaceuticals Latest Developments
13.5 Samsung Bioepis
13.5.1 Samsung Bioepis Company Information
13.5.2 Samsung Bioepis Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.5.3 Samsung Bioepis Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Samsung Bioepis Main Business Overview
13.5.5 Samsung Bioepis Latest Developments
13.6 Biocon Biologics
13.6.1 Biocon Biologics Company Information
13.6.2 Biocon Biologics Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.6.3 Biocon Biologics Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Biocon Biologics Main Business Overview
13.6.5 Biocon Biologics Latest Developments
13.7 Chengdu Kanghong Pharmaceutical
13.7.1 Chengdu Kanghong Pharmaceutical Company Information
13.7.2 Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.7.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Chengdu Kanghong Pharmaceutical Main Business Overview
13.7.5 Chengdu Kanghong Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Anti-VEGF Ophthalmic Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-VEGF Ophthalmic Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies
Table 4. Major Players ofFusion Proteins
Table 5. Global Anti-VEGF Ophthalmic Drugs Sales byType (2019-2024) & (K Dose)
Table 6. Global Anti-VEGF Ophthalmic Drugs Sales Market Share byType (2019-2024)
Table 7. Global Anti-VEGF Ophthalmic Drugs Revenue byType (2019-2024) & ($ million)
Table 8. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share byType (2019-2024)
Table 9. Global Anti-VEGF Ophthalmic Drugs Sale Price byType (2019-2024) & (US$/Dose)
Table 10. Global Anti-VEGF Ophthalmic Drugs Sale by Application (2019-2024) & (K Dose)
Table 11. Global Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2019-2024)
Table 12. Global Anti-VEGF Ophthalmic Drugs Revenue by Application (2019-2024) & ($ million)
Table 13. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2019-2024)
Table 14. Global Anti-VEGF Ophthalmic Drugs Sale Price by Application (2019-2024) & (US$/Dose)
Table 15. Global Anti-VEGF Ophthalmic Drugs Sales by Company (2019-2024) & (K Dose)
Table 16. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Company (2019-2024)
Table 17. Global Anti-VEGF Ophthalmic Drugs Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company (2019-2024)
Table 19. Global Anti-VEGF Ophthalmic Drugs Sale Price by Company (2019-2024) & (US$/Dose)
Table 20. Key Manufacturers Anti-VEGF Ophthalmic Drugs Producing Area Distribution and Sales Area
Table 21. Players Anti-VEGF Ophthalmic Drugs Products Offered
Table 22. Anti-VEGF Ophthalmic Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Anti-VEGF Ophthalmic Drugs Sales by Geographic Region (2019-2024) & (K Dose)
Table 26. Global Anti-VEGF Ophthalmic Drugs Sales Market Share Geographic Region (2019-2024)
Table 27. Global Anti-VEGF Ophthalmic Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Anti-VEGF Ophthalmic Drugs Sales by Country/Region (2019-2024) & (K Dose)
Table 30. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2019-2024)
Table 31. Global Anti-VEGF Ophthalmic Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Dose)
Table 34. Americas Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2024)
Table 35. Americas Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Anti-VEGF Ophthalmic Drugs Sales byType (2019-2024) & (K Dose)
Table 37. Americas Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024) & (K Dose)
Table 38. APAC Anti-VEGF Ophthalmic Drugs Sales by Region (2019-2024) & (K Dose)
Table 39. APAC Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2019-2024)
Table 40. APAC Anti-VEGF Ophthalmic Drugs Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Anti-VEGF Ophthalmic Drugs Sales byType (2019-2024) & (K Dose)
Table 42. APAC Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024) & (K Dose)
Table 43. Europe Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Dose)
Table 44. Europe Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Anti-VEGF Ophthalmic Drugs Sales byType (2019-2024) & (K Dose)
Table 46. Europe Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024) & (K Dose)
Table 47. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Dose)
Table 48. Middle East & Africa Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales byType (2019-2024) & (K Dose)
Table 50. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024) & (K Dose)
Table 51. Key Market Drivers & Growth Opportunities of Anti-VEGF Ophthalmic Drugs
Table 52. Key Market Challenges & Risks of Anti-VEGF Ophthalmic Drugs
Table 53. Key IndustryTrends of Anti-VEGF Ophthalmic Drugs
Table 54. Anti-VEGF Ophthalmic Drugs Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Anti-VEGF Ophthalmic Drugs Distributors List
Table 57. Anti-VEGF Ophthalmic Drugs Customer List
Table 58. Global Anti-VEGF Ophthalmic Drugs SalesForecast by Region (2025-2030) & (K Dose)
Table 59. Global Anti-VEGF Ophthalmic Drugs RevenueForecast by Region (2025-2030) & ($ millions)
Table 60. Americas Anti-VEGF Ophthalmic Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 61. Americas Anti-VEGF Ophthalmic Drugs Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 62. APAC Anti-VEGF Ophthalmic Drugs SalesForecast by Region (2025-2030) & (K Dose)
Table 63. APAC Anti-VEGF Ophthalmic Drugs Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 64. Europe Anti-VEGF Ophthalmic Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 65. Europe Anti-VEGF Ophthalmic Drugs RevenueForecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Anti-VEGF Ophthalmic Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 67. Middle East & Africa Anti-VEGF Ophthalmic Drugs RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Global Anti-VEGF Ophthalmic Drugs SalesForecast byType (2025-2030) & (K Dose)
Table 69. Global Anti-VEGF Ophthalmic Drugs RevenueForecast byType (2025-2030) & ($ millions)
Table 70. Global Anti-VEGF Ophthalmic Drugs SalesForecast by Application (2025-2030) & (K Dose)
Table 71. Global Anti-VEGF Ophthalmic Drugs RevenueForecast by Application (2025-2030) & ($ millions)
Table 72. Roche Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 73. Roche Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 74. Roche Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. Roche Main Business
Table 76. Roche Latest Developments
Table 77. Novartis Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Novartis Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 79. Novartis Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80. Novartis Main Business
Table 81. Novartis Latest Developments
Table 82. Coherus BioSciences Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Coherus BioSciences Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 84. Coherus BioSciences Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. Coherus BioSciences Main Business
Table 86. Coherus BioSciences Latest Developments
Table 87. Regeneron Pharmaceuticals Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 89. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. Regeneron Pharmaceuticals Main Business
Table 91. Regeneron Pharmaceuticals Latest Developments
Table 92. Samsung Bioepis Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Samsung Bioepis Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 94. Samsung Bioepis Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 95. Samsung Bioepis Main Business
Table 96. Samsung Bioepis Latest Developments
Table 97. Biocon Biologics Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Biocon Biologics Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 99. Biocon Biologics Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 100. Biocon Biologics Main Business
Table 101. Biocon Biologics Latest Developments
Table 102. Chengdu Kanghong Pharmaceutical Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 104. Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 105. Chengdu Kanghong Pharmaceutical Main Business
Table 106. Chengdu Kanghong Pharmaceutical Latest Developments
LIST OFFIGURES
Figure 1. Picture of Anti-VEGF Ophthalmic Drugs
Figure 2. Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Ophthalmic Drugs Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Anti-VEGF Ophthalmic Drugs Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Anti-VEGF Ophthalmic Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2023)
Figure 10. Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Monoclonal Antibodies
Figure 12. Product Picture ofFusion Proteins
Figure 13. Global Anti-VEGF Ophthalmic Drugs Sales Market Share byType in 2023
Figure 14. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share byType (2019-2024)
Figure 15. Anti-VEGF Ophthalmic Drugs Consumed in Age-related Macular Degeneration
Figure 16. Global Anti-VEGF Ophthalmic Drugs Market: Age-related Macular Degeneration (2019-2024) & (K Dose)
Figure 17. Anti-VEGF Ophthalmic Drugs Consumed in Diabetic Retinopathy
Figure 18. Global Anti-VEGF Ophthalmic Drugs Market: Diabetic Retinopathy (2019-2024) & (K Dose)
Figure 19. Anti-VEGF Ophthalmic Drugs Consumed in Other
Figure 20. Global Anti-VEGF Ophthalmic Drugs Market: Other (2019-2024) & (K Dose)
Figure 21. Global Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2023)
Figure 22. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application in 2023
Figure 23. Anti-VEGF Ophthalmic Drugs Sales by Company in 2023 (K Dose)
Figure 24. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Company in 2023
Figure 25. Anti-VEGF Ophthalmic Drugs Revenue by Company in 2023 ($ millions)
Figure 26. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company in 2023
Figure 27. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Anti-VEGF Ophthalmic Drugs Sales 2019-2024 (K Dose)
Figure 30. Americas Anti-VEGF Ophthalmic Drugs Revenue 2019-2024 ($ millions)
Figure 31. APAC Anti-VEGF Ophthalmic Drugs Sales 2019-2024 (K Dose)
Figure 32. APAC Anti-VEGF Ophthalmic Drugs Revenue 2019-2024 ($ millions)
Figure 33. Europe Anti-VEGF Ophthalmic Drugs Sales 2019-2024 (K Dose)
Figure 34. Europe Anti-VEGF Ophthalmic Drugs Revenue 2019-2024 ($ millions)
Figure 35. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales 2019-2024 (K Dose)
Figure 36. Middle East & Africa Anti-VEGF Ophthalmic Drugs Revenue 2019-2024 ($ millions)
Figure 37. Americas Anti-VEGF Ophthalmic Drugs Sales Market Share by Country in 2023
Figure 38. Americas Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2024)
Figure 39. Americas Anti-VEGF Ophthalmic Drugs Sales Market Share byType (2019-2024)
Figure 40. Americas Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2024)
Figure 41. United States Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 42. Canada Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 43. Mexico Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 44. Brazil Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 45. APAC Anti-VEGF Ophthalmic Drugs Sales Market Share by Region in 2023
Figure 46. APAC Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2019-2024)
Figure 47. APAC Anti-VEGF Ophthalmic Drugs Sales Market Share byType (2019-2024)
Figure 48. APAC Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2024)
Figure 49. China Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 50. Japan Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 51. South Korea Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 52. Southeast Asia Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 53. India Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 54. Australia Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 55. ChinaTaiwan Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 56. Europe Anti-VEGF Ophthalmic Drugs Sales Market Share by Country in 2023
Figure 57. Europe Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2024)
Figure 58. Europe Anti-VEGF Ophthalmic Drugs Sales Market Share byType (2019-2024)
Figure 59. Europe Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2024)
Figure 60. Germany Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 61.France Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 62. UK Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 63. Italy Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 64. Russia Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 65. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2024)
Figure 66. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales Market Share byType (2019-2024)
Figure 67. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2024)
Figure 68. Egypt Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 69. South Africa Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 70. Israel Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 71.Turkey Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 72. GCC Countries Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Anti-VEGF Ophthalmic Drugs in 2023
Figure 74. Manufacturing Process Analysis of Anti-VEGF Ophthalmic Drugs
Figure 75. Industry Chain Structure of Anti-VEGF Ophthalmic Drugs
Figure 76. Channels of Distribution
Figure 77. Global Anti-VEGF Ophthalmic Drugs Sales MarketForecast by Region (2025-2030)
Figure 78. Global Anti-VEGF Ophthalmic Drugs Revenue Market ShareForecast by Region (2025-2030)
Figure 79. Global Anti-VEGF Ophthalmic Drugs Sales Market ShareForecast byType (2025-2030)
Figure 80. Global Anti-VEGF Ophthalmic Drugs Revenue Market ShareForecast byType (2025-2030)
Figure 81. Global Anti-VEGF Ophthalmic Drugs Sales Market ShareForecast by Application (2025-2030)
Figure 82. Global Anti-VEGF Ophthalmic Drugs Revenue Market ShareForecast by Application (2025-2030)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Ophthalmic Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Anti-VEGF Ophthalmic Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Anti-VEGF Ophthalmic Drugs by Country/Region, 2019, 2023 & 2030
2.2 Anti-VEGF Ophthalmic Drugs Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Fusion Proteins
2.3 Anti-VEGF Ophthalmic Drugs Sales by Type
2.3.1 Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Anti-VEGF Ophthalmic Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Anti-VEGF Ophthalmic Drugs Sale Price by Type (2019-2024)
2.4 Anti-VEGF Ophthalmic Drugs Segment by Application
2.4.1 Age-related Macular Degeneration
2.4.2 Diabetic Retinopathy
2.4.3 Other
2.5 Anti-VEGF Ophthalmic Drugs Sales by Application
2.5.1 Global Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Anti-VEGF Ophthalmic Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Anti-VEGF Ophthalmic Drugs Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Anti-VEGF Ophthalmic Drugs Breakdown Data by Company
3.1.1 Global Anti-VEGF Ophthalmic Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Company (2019-2024)
3.2 Global Anti-VEGF Ophthalmic Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Anti-VEGF Ophthalmic Drugs Revenue by Company (2019-2024)
3.2.2 Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Anti-VEGF Ophthalmic Drugs Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Ophthalmic Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Ophthalmic Drugs Product Location Distribution
3.4.2 Players Anti-VEGF Ophthalmic Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF OPHTHALMIC DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Ophthalmic Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Anti-VEGF Ophthalmic Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Anti-VEGF Ophthalmic Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Anti-VEGF Ophthalmic Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Anti-VEGF Ophthalmic Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Anti-VEGF Ophthalmic Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Anti-VEGF Ophthalmic Drugs Sales Growth
4.4 APAC Anti-VEGF Ophthalmic Drugs Sales Growth
4.5 Europe Anti-VEGF Ophthalmic Drugs Sales Growth
4.6 Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Ophthalmic Drugs Sales by Country
5.1.1 Americas Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024)
5.1.2 Americas Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024)
5.2 Americas Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2024)
5.3 Americas Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Ophthalmic Drugs Sales by Region
6.1.1 APAC Anti-VEGF Ophthalmic Drugs Sales by Region (2019-2024)
6.1.2 APAC Anti-VEGF Ophthalmic Drugs Revenue by Region (2019-2024)
6.2 APAC Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2024)
6.3 APAC Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Ophthalmic Drugs by Country
7.1.1 Europe Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024)
7.1.2 Europe Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024)
7.2 Europe Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2024)
7.3 Europe Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Ophthalmic Drugs by Country
8.1.1 Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2024)
8.3 Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Ophthalmic Drugs
10.3 Manufacturing Process Analysis of Anti-VEGF Ophthalmic Drugs
10.4 Industry Chain Structure of Anti-VEGF Ophthalmic Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Ophthalmic Drugs Distributors
11.3 Anti-VEGF Ophthalmic Drugs Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF OPHTHALMIC DRUGS BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Ophthalmic Drugs Market Size Forecast by Region
12.1.1 Global Anti-VEGF Ophthalmic Drugs Forecast by Region (2025-2030)
12.1.2 Global Anti-VEGF Ophthalmic Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Anti-VEGF Ophthalmic Drugs Forecast by Type (2025-2030)
12.7 Global Anti-VEGF Ophthalmic Drugs Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.1.3 Roche Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.2.3 Novartis Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Coherus BioSciences
13.3.1 Coherus BioSciences Company Information
13.3.2 Coherus BioSciences Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.3.3 Coherus BioSciences Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Coherus BioSciences Main Business Overview
13.3.5 Coherus BioSciences Latest Developments
13.4 Regeneron Pharmaceuticals
13.4.1 Regeneron Pharmaceuticals Company Information
13.4.2 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.4.3 Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Regeneron Pharmaceuticals Main Business Overview
13.4.5 Regeneron Pharmaceuticals Latest Developments
13.5 Samsung Bioepis
13.5.1 Samsung Bioepis Company Information
13.5.2 Samsung Bioepis Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.5.3 Samsung Bioepis Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Samsung Bioepis Main Business Overview
13.5.5 Samsung Bioepis Latest Developments
13.6 Biocon Biologics
13.6.1 Biocon Biologics Company Information
13.6.2 Biocon Biologics Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.6.3 Biocon Biologics Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Biocon Biologics Main Business Overview
13.6.5 Biocon Biologics Latest Developments
13.7 Chengdu Kanghong Pharmaceutical
13.7.1 Chengdu Kanghong Pharmaceutical Company Information
13.7.2 Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.7.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Chengdu Kanghong Pharmaceutical Main Business Overview
13.7.5 Chengdu Kanghong Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Anti-VEGF Ophthalmic Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Anti-VEGF Ophthalmic Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies
Table 4. Major Players ofFusion Proteins
Table 5. Global Anti-VEGF Ophthalmic Drugs Sales byType (2019-2024) & (K Dose)
Table 6. Global Anti-VEGF Ophthalmic Drugs Sales Market Share byType (2019-2024)
Table 7. Global Anti-VEGF Ophthalmic Drugs Revenue byType (2019-2024) & ($ million)
Table 8. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share byType (2019-2024)
Table 9. Global Anti-VEGF Ophthalmic Drugs Sale Price byType (2019-2024) & (US$/Dose)
Table 10. Global Anti-VEGF Ophthalmic Drugs Sale by Application (2019-2024) & (K Dose)
Table 11. Global Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2019-2024)
Table 12. Global Anti-VEGF Ophthalmic Drugs Revenue by Application (2019-2024) & ($ million)
Table 13. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2019-2024)
Table 14. Global Anti-VEGF Ophthalmic Drugs Sale Price by Application (2019-2024) & (US$/Dose)
Table 15. Global Anti-VEGF Ophthalmic Drugs Sales by Company (2019-2024) & (K Dose)
Table 16. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Company (2019-2024)
Table 17. Global Anti-VEGF Ophthalmic Drugs Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company (2019-2024)
Table 19. Global Anti-VEGF Ophthalmic Drugs Sale Price by Company (2019-2024) & (US$/Dose)
Table 20. Key Manufacturers Anti-VEGF Ophthalmic Drugs Producing Area Distribution and Sales Area
Table 21. Players Anti-VEGF Ophthalmic Drugs Products Offered
Table 22. Anti-VEGF Ophthalmic Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Anti-VEGF Ophthalmic Drugs Sales by Geographic Region (2019-2024) & (K Dose)
Table 26. Global Anti-VEGF Ophthalmic Drugs Sales Market Share Geographic Region (2019-2024)
Table 27. Global Anti-VEGF Ophthalmic Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Anti-VEGF Ophthalmic Drugs Sales by Country/Region (2019-2024) & (K Dose)
Table 30. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2019-2024)
Table 31. Global Anti-VEGF Ophthalmic Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Dose)
Table 34. Americas Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2024)
Table 35. Americas Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Anti-VEGF Ophthalmic Drugs Sales byType (2019-2024) & (K Dose)
Table 37. Americas Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024) & (K Dose)
Table 38. APAC Anti-VEGF Ophthalmic Drugs Sales by Region (2019-2024) & (K Dose)
Table 39. APAC Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2019-2024)
Table 40. APAC Anti-VEGF Ophthalmic Drugs Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Anti-VEGF Ophthalmic Drugs Sales byType (2019-2024) & (K Dose)
Table 42. APAC Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024) & (K Dose)
Table 43. Europe Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Dose)
Table 44. Europe Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Anti-VEGF Ophthalmic Drugs Sales byType (2019-2024) & (K Dose)
Table 46. Europe Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024) & (K Dose)
Table 47. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Dose)
Table 48. Middle East & Africa Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales byType (2019-2024) & (K Dose)
Table 50. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024) & (K Dose)
Table 51. Key Market Drivers & Growth Opportunities of Anti-VEGF Ophthalmic Drugs
Table 52. Key Market Challenges & Risks of Anti-VEGF Ophthalmic Drugs
Table 53. Key IndustryTrends of Anti-VEGF Ophthalmic Drugs
Table 54. Anti-VEGF Ophthalmic Drugs Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Anti-VEGF Ophthalmic Drugs Distributors List
Table 57. Anti-VEGF Ophthalmic Drugs Customer List
Table 58. Global Anti-VEGF Ophthalmic Drugs SalesForecast by Region (2025-2030) & (K Dose)
Table 59. Global Anti-VEGF Ophthalmic Drugs RevenueForecast by Region (2025-2030) & ($ millions)
Table 60. Americas Anti-VEGF Ophthalmic Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 61. Americas Anti-VEGF Ophthalmic Drugs Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 62. APAC Anti-VEGF Ophthalmic Drugs SalesForecast by Region (2025-2030) & (K Dose)
Table 63. APAC Anti-VEGF Ophthalmic Drugs Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 64. Europe Anti-VEGF Ophthalmic Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 65. Europe Anti-VEGF Ophthalmic Drugs RevenueForecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Anti-VEGF Ophthalmic Drugs SalesForecast by Country (2025-2030) & (K Dose)
Table 67. Middle East & Africa Anti-VEGF Ophthalmic Drugs RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Global Anti-VEGF Ophthalmic Drugs SalesForecast byType (2025-2030) & (K Dose)
Table 69. Global Anti-VEGF Ophthalmic Drugs RevenueForecast byType (2025-2030) & ($ millions)
Table 70. Global Anti-VEGF Ophthalmic Drugs SalesForecast by Application (2025-2030) & (K Dose)
Table 71. Global Anti-VEGF Ophthalmic Drugs RevenueForecast by Application (2025-2030) & ($ millions)
Table 72. Roche Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 73. Roche Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 74. Roche Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. Roche Main Business
Table 76. Roche Latest Developments
Table 77. Novartis Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Novartis Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 79. Novartis Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80. Novartis Main Business
Table 81. Novartis Latest Developments
Table 82. Coherus BioSciences Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Coherus BioSciences Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 84. Coherus BioSciences Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. Coherus BioSciences Main Business
Table 86. Coherus BioSciences Latest Developments
Table 87. Regeneron Pharmaceuticals Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 89. Regeneron Pharmaceuticals Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. Regeneron Pharmaceuticals Main Business
Table 91. Regeneron Pharmaceuticals Latest Developments
Table 92. Samsung Bioepis Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Samsung Bioepis Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 94. Samsung Bioepis Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 95. Samsung Bioepis Main Business
Table 96. Samsung Bioepis Latest Developments
Table 97. Biocon Biologics Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Biocon Biologics Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 99. Biocon Biologics Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 100. Biocon Biologics Main Business
Table 101. Biocon Biologics Latest Developments
Table 102. Chengdu Kanghong Pharmaceutical Basic Information, Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 104. Chengdu Kanghong Pharmaceutical Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 105. Chengdu Kanghong Pharmaceutical Main Business
Table 106. Chengdu Kanghong Pharmaceutical Latest Developments
LIST OFFIGURES
Figure 1. Picture of Anti-VEGF Ophthalmic Drugs
Figure 2. Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Ophthalmic Drugs Sales Growth Rate 2019-2030 (K Dose)
Figure 7. Global Anti-VEGF Ophthalmic Drugs Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Anti-VEGF Ophthalmic Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2023)
Figure 10. Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Monoclonal Antibodies
Figure 12. Product Picture ofFusion Proteins
Figure 13. Global Anti-VEGF Ophthalmic Drugs Sales Market Share byType in 2023
Figure 14. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share byType (2019-2024)
Figure 15. Anti-VEGF Ophthalmic Drugs Consumed in Age-related Macular Degeneration
Figure 16. Global Anti-VEGF Ophthalmic Drugs Market: Age-related Macular Degeneration (2019-2024) & (K Dose)
Figure 17. Anti-VEGF Ophthalmic Drugs Consumed in Diabetic Retinopathy
Figure 18. Global Anti-VEGF Ophthalmic Drugs Market: Diabetic Retinopathy (2019-2024) & (K Dose)
Figure 19. Anti-VEGF Ophthalmic Drugs Consumed in Other
Figure 20. Global Anti-VEGF Ophthalmic Drugs Market: Other (2019-2024) & (K Dose)
Figure 21. Global Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2023)
Figure 22. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application in 2023
Figure 23. Anti-VEGF Ophthalmic Drugs Sales by Company in 2023 (K Dose)
Figure 24. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Company in 2023
Figure 25. Anti-VEGF Ophthalmic Drugs Revenue by Company in 2023 ($ millions)
Figure 26. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company in 2023
Figure 27. Global Anti-VEGF Ophthalmic Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 28. Global Anti-VEGF Ophthalmic Drugs Revenue Market Share by Geographic Region in 2023
Figure 29. Americas Anti-VEGF Ophthalmic Drugs Sales 2019-2024 (K Dose)
Figure 30. Americas Anti-VEGF Ophthalmic Drugs Revenue 2019-2024 ($ millions)
Figure 31. APAC Anti-VEGF Ophthalmic Drugs Sales 2019-2024 (K Dose)
Figure 32. APAC Anti-VEGF Ophthalmic Drugs Revenue 2019-2024 ($ millions)
Figure 33. Europe Anti-VEGF Ophthalmic Drugs Sales 2019-2024 (K Dose)
Figure 34. Europe Anti-VEGF Ophthalmic Drugs Revenue 2019-2024 ($ millions)
Figure 35. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales 2019-2024 (K Dose)
Figure 36. Middle East & Africa Anti-VEGF Ophthalmic Drugs Revenue 2019-2024 ($ millions)
Figure 37. Americas Anti-VEGF Ophthalmic Drugs Sales Market Share by Country in 2023
Figure 38. Americas Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2024)
Figure 39. Americas Anti-VEGF Ophthalmic Drugs Sales Market Share byType (2019-2024)
Figure 40. Americas Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2024)
Figure 41. United States Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 42. Canada Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 43. Mexico Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 44. Brazil Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 45. APAC Anti-VEGF Ophthalmic Drugs Sales Market Share by Region in 2023
Figure 46. APAC Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2019-2024)
Figure 47. APAC Anti-VEGF Ophthalmic Drugs Sales Market Share byType (2019-2024)
Figure 48. APAC Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2024)
Figure 49. China Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 50. Japan Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 51. South Korea Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 52. Southeast Asia Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 53. India Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 54. Australia Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 55. ChinaTaiwan Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 56. Europe Anti-VEGF Ophthalmic Drugs Sales Market Share by Country in 2023
Figure 57. Europe Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2024)
Figure 58. Europe Anti-VEGF Ophthalmic Drugs Sales Market Share byType (2019-2024)
Figure 59. Europe Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2024)
Figure 60. Germany Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 61.France Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 62. UK Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 63. Italy Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 64. Russia Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 65. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2024)
Figure 66. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales Market Share byType (2019-2024)
Figure 67. Middle East & Africa Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2024)
Figure 68. Egypt Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 69. South Africa Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 70. Israel Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 71.Turkey Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 72. GCC Countries Anti-VEGF Ophthalmic Drugs Revenue Growth 2019-2024 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Anti-VEGF Ophthalmic Drugs in 2023
Figure 74. Manufacturing Process Analysis of Anti-VEGF Ophthalmic Drugs
Figure 75. Industry Chain Structure of Anti-VEGF Ophthalmic Drugs
Figure 76. Channels of Distribution
Figure 77. Global Anti-VEGF Ophthalmic Drugs Sales MarketForecast by Region (2025-2030)
Figure 78. Global Anti-VEGF Ophthalmic Drugs Revenue Market ShareForecast by Region (2025-2030)
Figure 79. Global Anti-VEGF Ophthalmic Drugs Sales Market ShareForecast byType (2025-2030)
Figure 80. Global Anti-VEGF Ophthalmic Drugs Revenue Market ShareForecast byType (2025-2030)
Figure 81. Global Anti-VEGF Ophthalmic Drugs Sales Market ShareForecast by Application (2025-2030)
Figure 82. Global Anti-VEGF Ophthalmic Drugs Revenue Market ShareForecast by Application (2025-2030)
